These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10606300)

  • 21. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
    Endzinas Z; Mickevicius A; Kiudelis M
    Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance of Barrett's oesophagus: is it worthwhile?
    Somerville M; Garside R; Pitt M; Stein K
    Eur J Cancer; 2008 Mar; 44(4):588-99. PubMed ID: 18272361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
    Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
    Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy.
    Abela JE; Going JJ; Mackenzie JF; McKernan M; O'Mahoney S; Stuart RC
    Am J Gastroenterol; 2008 Apr; 103(4):850-5. PubMed ID: 18371135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoprevention of esophageal cancer: endoscopic ablation of Barrett's metaplasia and dysplasia.
    Wolfsen HC
    Expert Rev Med Devices; 2005 Nov; 2(6):713-23. PubMed ID: 16293098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of Barrett's high-grade dysplasia.
    Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
    Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program.
    Shaheen NJ; Green B; Medapalli RK; Mitchell KL; Wei JT; Schmitz SM; West LM; Brown A; Noble M; Sultan S; Provenzale D
    Gastroenterology; 2005 Aug; 129(2):429-36. PubMed ID: 16083700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting.
    Eloubeidi MA; Homan RK; Martz MD; Theobald KE; Provenzale D
    Am J Gastroenterol; 1999 Aug; 94(8):2033-6. PubMed ID: 10445524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
    Downs-Kelly E; Mendelin JE; Bennett AE; Castilla E; Henricks WH; Schoenfield L; Skacel M; Yerian L; Rice TW; Rybicki LA; Bronner MP; Goldblum JR
    Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
    Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
    Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
    Armstrong D
    Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
    Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
    Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
    Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
    Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma.
    Guardino JM; Khandwala F; Lopez R; Wachsberger DM; Richter JE; Falk GW
    Am J Gastroenterol; 2006 Oct; 101(10):2187-93. PubMed ID: 17032182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?
    Soni A; Sampliner RE; Sonnenberg A
    Am J Gastroenterol; 2000 Aug; 95(8):2086-93. PubMed ID: 10950062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.